Alkem Labs & Biocon Jump Over 3% On Receiving Nods From USFDA

Pharma majors, Alkem Labs and Biocon jumped over 3% on Wednesday, after getting approval from US FDA. The US drug regulator approved the Exemestane tablets of Mylan, which is a partner of Biocon. These tablets are used to treat breast cancer.

Whereas, the regulator gave a nod for Lidocaine ointment of Alkem Labs, which is used to treat ventricular tachycardia.

Alkem Labs in the past one month is up by over 5%, and it has touched an intraday high of Rs 1998.25 per share; while Biocon is up nearly 4% over the past one month, and hit an intraday high of Rs 1124.90 per share. Biocon has delivered 134% returns; and Alkem Labs has delivered 44% returns in a period of one year.

For Quick Trial – 8962000225 ✔
or mail us here:
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717
Share on Google Plus Share on Pinterest

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.